Literature DB >> 12527956

Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index.

Declan Walsh1, Fade Mahmoud, Barbara Barna.   

Abstract

The Prognostic Inflammatory Nutritional Index (PINI) is a simple scoring system that has been used to evaluate nutritional status and prognosis in critically ill patients. The PINI has never been evaluated in advanced cancer. Fifty consecutive patients with advanced cancer, weight loss, and anorexia were studied. C-reactive protein (CRP), albumin, pre-albumin, interleukin-6 (IL-6), and alpha 1-acid glycoprotein (AAG) were evaluated. The individual values for AAG, CRP, and IL-6 were markedly elevated. In contrast to albumin and prealbumin, CRP levels were very high. The PINI was significantly elevated, and higher than reported in critically ill intensive care patients. Elevated IL-6 levels correlated with high PINI and CRP values. CRP, IL-6, and PINI should be considered in future research on nutritional status and prediction of prognosis in advanced cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12527956     DOI: 10.1007/s00520-002-0390-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  14 in total

1.  Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data.

Authors:  Tonya S Orchard; Rebecca R Andridge; Lisa D Yee; Maryam B Lustberg
Journal:  J Acad Nutr Diet       Date:  2017-12-09       Impact factor: 4.910

2.  Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.

Authors:  Drazena Srdic; Sanja Plestina; Ana Sverko-Peternac; Nora Nikolac; Ana-Maria Simundic; Miroslav Samarzija
Journal:  Support Care Cancer       Date:  2016-05-28       Impact factor: 3.603

3.  Orosomucoid is an independent predictor of prognosis in chronic heart failure.

Authors:  Petra Kaplan; Bojan Vrtovec; Borut Jug
Journal:  Wien Klin Wochenschr       Date:  2016-07-05       Impact factor: 1.704

4.  Evaluation of recovery in iatrogenic evoked acute mediatinitis.

Authors:  Sławomir Jabłoński; Marcin Kozakiewicz
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

5.  Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy.

Authors:  Dawn Wiese; Bret Lashner; Douglas Seidner
Journal:  Nutr Clin Pract       Date:  2008 Oct-Nov       Impact factor: 3.080

6.  Proposal for a recovery prediction method for patients affected by acute mediastinitis.

Authors:  Sławomir Jabłoński; Marcin Kozakiewicz
Journal:  World J Emerg Surg       Date:  2012-05-10       Impact factor: 5.469

Review 7.  C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review.

Authors:  Shiva Shrotriya; Declan Walsh; Nabila Bennani-Baiti; Shirley Thomas; Cliona Lorton
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

Review 8.  Protein calorie malnutrition, nutritional intervention and personalized cancer care.

Authors:  Anju Gangadharan; Sung Eun Choi; Ahmed Hassan; Nehad M Ayoub; Gina Durante; Sakshi Balwani; Young Hee Kim; Andrew Pecora; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2017-04-04

9.  Wheel Balanced Cancer Therapy for Longer Than 21 Days Can Have a Positive Effect on the Survival of Patients with Stage IV Cancer.

Authors:  Hyung-Joon Jeon; Jong-Min Kim; Chong-Kwan Cho; Yeon-Weol Lee; Hwa-Seung Yoo
Journal:  J Pharmacopuncture       Date:  2015-09

10.  Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors.

Authors:  Sung Hoon Sim; Seung-Hoon Beom; Yong-Oon Ahn; Bhumsuk Keam; Tae Min Kim; Se-Hoon Lee; Dong-Wan Kim; Dae Seog Heo
Journal:  Thorac Cancer       Date:  2015-08-28       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.